📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Pharvaris

1.1 - Company Overview

Pharvaris Logo

Pharvaris

Headquarter: Switzerland
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of oral bradykinin B2-receptor antagonist therapies in clinical development for hereditary angioedema (HAE), including deucrictibant; PHVS416 immediate-release capsules for acute HAE attacks; PHVS719 extended-release tablets for HAE prophylaxis; and the RAPIDe-1, RAPIDe-2, and CHAPTER-1 clinical trials evaluating these candidates.

Products and services

  • Deucrictibant: A clinical-stage oral bradykinin B2-receptor antagonist in development to treat hereditary angioedema, employing novel small molecules as alternatives to injected therapies across HAE sub-types
  • PHVS719: An extended-release tablet developed to maintain therapeutic exposure for over 24 hours, intended for prophylactic treatment of hereditary angioedema via sustained oral B2-receptor antagonism
  • PHVS416: An immediate-release capsule engineered for rapid therapeutic exposure to treat acute hereditary angioedema attacks, designed for fast on-demand use assessed in clinical studies

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Pharvaris

Cydan Logo

Cydan

HQ: United States Website
  • Description: Provider of orphan drug accelerator services focused on identifying and de-risking compounds with therapeutic and commercial potential.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Cydan company profile →
Astria Therapeutics Logo

Astria Therapeutics

HQ: United States Website
  • Description: Provider of drug discovery and development for inflammatory conditions, with a pipeline including STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein for long-acting prevention of hereditary angioedema (potentially dosed every 3 to 6 months), STAR-0310, a monoclonal antibody OX40 antagonist for atopic dermatitis, and the ALPHA-STAR Phase 1b/2 trial evaluating STAR-0215 in HAE types I and II.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Astria Therapeutics company profile →
Aeovian Pharmaceuticals Logo

Aeovian Pharmaceuticals

HQ: United States Website
  • Description: Provider of therapeutics for rare and age-related diseases, focused on discovering, developing, and commercializing treatments.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aeovian Pharmaceuticals company profile →
Mitobridge Logo

Mitobridge

HQ: United States Website
  • Description: Provider of small molecule therapeutics that improve mitochondrial function to address diseases with high unmet need. Pipeline includes investigational candidates: ASP0367 for primary mitochondrial myopathies and Duchenne muscular dystrophy, ASP1128 for acute kidney injury, and an NAD+ modulation program targeting aging-related conditions.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Mitobridge company profile →
Chiasma Logo

Chiasma

HQ: United States Website
  • Description: Provider of biopharmaceutical solutions developing oral drugs for orphan diseases using proprietary Transient Permeability Enhancer technology to convert approved injectables to oral formulations, potentially enabling new indications and enhanced absorption by promoting delivery to the GI wall and liver.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Chiasma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Pharvaris

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Pharvaris

2.2 - Growth funds investing in similar companies to Pharvaris

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Pharvaris

4.2 - Public trading comparable groups for Pharvaris

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Pharvaris

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Pharvaris

What does Pharvaris do?

Pharvaris is a provider of oral bradykinin B2-receptor antagonist therapies in clinical development for hereditary angioedema (HAE), including deucrictibant; PHVS416 immediate-release capsules for acute HAE attacks; PHVS719 extended-release tablets for HAE prophylaxis; and the RAPIDe-1, RAPIDe-2, and CHAPTER-1 clinical trials evaluating these candidates.

Who are Pharvaris's competitors?

Pharvaris's competitors and similar companies include Cydan, Astria Therapeutics, Aeovian Pharmaceuticals, Mitobridge, and Chiasma.

Where is Pharvaris headquartered?

Pharvaris is headquartered in Switzerland.

How many employees does Pharvaris have?

Pharvaris has 1,000 employees 🔒.

When was Pharvaris founded?

Pharvaris was founded in 2010 🔒.

What sector and industry vertical is Pharvaris in?

Pharvaris is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Pharvaris

Who are the top strategic acquirers in Pharvaris's sector and industry

Top strategic M&A buyers and acquirers in Pharvaris's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Pharvaris?

Top strategic M&A buyers groups and sectors for Pharvaris include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Pharvaris's sector and industry vertical

Which are the top PE firms investing in Pharvaris's sector and industry vertical?

Top PE firms investing in Pharvaris's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Pharvaris's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Pharvaris's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Pharvaris's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Pharvaris include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Pharvaris's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Pharvaris?

The key public trading comparables and valuation benchmarks for Pharvaris include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Pharvaris for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Pharvaris with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Pharvaris's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Pharvaris with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Pharvaris's' sector and industry vertical?

Access recent funding rounds and capital raises in Pharvaris's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Pharvaris